Boston, MA 04/08/2014 (wallstreetpr) – Peregrine Pharmaceuticals (NASDAQ:PPHM) has introduced monoclonal antibodies for the diagnosis and treatment of cancerous cells present in the body. The U.S. based bio pharmaceutical company has reported that this very invention will help in opening a new horizon in the medical science.
Announcement of the 3-abstracts of the company:
The company has scheduled a poster presentation in order to present the 3-abstracts on the upcoming 105th annual meeting of AACR (Ameriacan Association for cancer Research). The presentation meet will be held from April 5 to April 9, 2014. The paper presentation venue has been selected as San Diego, California.
Brief overview of the 3-Abstract details:
The detailed presentation on the abstract number-639, LB-262 and 4978 will take place on the San Diego venue, explaining the survival and eradication of a small cell cancer and the antibody to check tumor growth. Panel of 14 members will be present there to judge the scenario.
Peregrine Pharmaceuticals (NASDAQ:PPHM) latest updates:
On April 7, 2014 Peregrine Pharmaceuticals (NASDAQ:PPHM)’s share went up by 6.53% and reached the value of $1.96. The latest announcement on the company stating the abstracts on the cancerous cell detection, analysis and resolution has gone in favor of the company’s reputation. An investigational immunotherapy, Bavituximab is being evaluated presently in NSCLC (Non Small Cell Lung Cancer).
These impressive studies show a survival development on lung cancer treatment and reduction. After this sensational quote, Dr. Jeff T. Hutchins vice president of Peregrine Pharmaceuticals (NASDAQ:PPHM) demonstrated the considerable remedies of bavituximab activity.
Treatment effect on the specimen:
The study conducted on rats has come up with some amazing facts. Rats were injected twice on 3×12 Gy radiations only or 3×12 Gy combined with 2aG4. The latter has been considered with 67% success rate on 100% survival of the creatures after the 184 days of application. On the flip side, the success rate goes down. Now, it’s time to wait and see how much effective it is while applying on human cancerous cells!!
